Effects of GLP1 agonist liRAglutiDE in patients with antispychotic-drUgs-associATEd diabetes mellitus

Trial Profile

Effects of GLP1 agonist liRAglutiDE in patients with antispychotic-drUgs-associATEd diabetes mellitus

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2015

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GRADUATE
  • Most Recent Events

    • 09 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top